Jiawa (ལྕ་བ་) in Tibetan Medicine: A Review of Multi-Origin Use, Shared and Differential Chemical Constituents, and Pharmacological Relevance to Huangshui-Associated Joint Disorders

Jiawa (Wylie: lca ba) is a multi-origin Tibetan medicinal material used in classical prescriptions for Huangshui (Wylie: chu ser) disorders. This review summarizes traditional, phytochemical, and pharmacological evidence to discuss how the traditional use of Jiawa-related materials in Huangshui-associated joint disorders may be interpreted. Classical materia medica records, official standards, regional medicinal-use reports, and biomedical literature were integrated, with emphasis on three representative Jiawa-related sources: Vicatia thibetica de Boiss., Sphallerocarpus gracilis (Bess.) K.-Pol., and Pleurospermum hookeri C. B. Clarke var. thomsonii C. B. Clarke. The currently available phytochemical evidence indicates that these three sources differ in their reported chemical profiles, while several constituents have been documented in more than one source. Among the constituents reported from at least two representative sources, β-sitosterol, bergapten, ferulic acid, 3,5-dicaffeoylquinic acid, ligustilide, daucosterol, and isoimperatorin have been studied in arthritis-related experimental models involving inflammation, oxidative stress, immune regulation, angiogenesis, cartilage or bone damage, and pain signaling. In addition, constituents reported from individual sources are discussed according to the available constituent-level evidence. These studies mainly involve inflammation, oxidative stress, synovial hyperplasia, and bone metabolism for V. thibetica; inflammatory-pathway modulation for S. gracilis; and immune regulation, antioxidant protection, and cartilage or matrix preservation for P. hookeri var. thomsonii. Taken together, the available evidence provides preliminary chemical and pharmacological clues for understanding the traditional use of Jiawa-related materials in Huangshui-associated joint disorders. However, these observations are based mainly on phytochemical reports and constituent-level pharmacological studies. The relevance of these findings to authenticated Jiawa-related medicinal materials and Huangshui-associated disorders therefore requires further verification through direct comparative studies.